Letter to the Editor
Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19

https://doi.org/10.1016/j.ejim.2022.11.014Get rights and content

Keywords

COVID-19
Severe disease
Mortality
Interleukin-1
Anakinra
Canakinumab

Cited by (0)

View Abstract